Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Merck
Express Scripts
Baxter
Dow
Mallinckrodt
Medtronic

Last Updated: November 19, 2019

DrugPatentWatch Database Preview

Details for Patent: 6,740,341

See Plans and Pricing

« Back to Dashboard

Which drugs does patent 6,740,341 protect, and when does it expire?

Patent 6,740,341 protects ORAPRED ODT and is included in one NDA.

This patent has nine patent family members in seven countries.

Summary for Patent: 6,740,341
Title: Taste masking rapid release coating system
Abstract:The present invention relates to a core containing a drug encased in a spacing layer and a taste masking layer which provides effective taste masking for in-mouth disintegrable dosage forms containing highly objectionable tasting drugs, as well as dosage forms containing these cores.
Inventor(s): Holt; Kris E. (Maple Grove, MN), Khankari; Rajendra K. (Maple Grove, MN), Hontz; John (Plymouth, MN)
Assignee: Cima Labs Inc. (Eden Prairie, MN)
Application Number:09/449,851
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 6,740,341
Patent Claim Types:
see list of patent claims
Use; Formulation; Composition; Dosage form;

Drugs Protected by US Patent 6,740,341

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-001 Jun 1, 2006 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-002 Jun 1, 2006 AB RX Yes No   Start Trial   Start Trial Y   Start Trial
Concordia Pharms Inc ORAPRED ODT prednisolone sodium phosphate TABLET, ORALLY DISINTEGRATING;ORAL 021959-003 Jun 1, 2006 AB RX Yes Yes   Start Trial   Start Trial Y   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 6,740,341

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 1922000   Start Trial
Australia 753476   Start Trial
Canada 2351720   Start Trial
European Patent Office 1133282   Start Trial
European Patent Office 2260836   Start Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Medtronic
AstraZeneca
Colorcon
Dow
McKesson
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.